RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

  • Regulatory NewsRegulatory News

    FDA revises REMS MAPP for new comparable ETASU provisions

    The US Food and Drug Administration (FDA) this week revised its manual of policies and procedures (MAPP) to reflect recent statutory changes that make it easier for drugmakers to develop separate risk evaluation and mitigation strategies (REMS) with comparable elements to assure safe use (ETASU).   The Further Consolidated Appropriations Act, 2020 , which was enacted late last year, included two provisions aimed at increasing generic and biosimilar competition.   ...
  • ReconRecon

    Recon: Regeneron to stop enrolling sickest patients in COVID antibody trials; AZ sells rights to two drugs for $400M

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US Regeneron to stop enrolling very sick COVID-19 patients in antibody trials ( Reuters ) ( Endpoints ) Inside Operation Warp Speed’s $18 Billion Sprint for a Vaccine ( Bloomberg ) Biden’s policies could spell trouble for biotech — but industry CEOs are backing him anyway ( STAT ) AbbVie Reports Third-Quarter 2020 Financial Results ( Press ) Medtronic to Pay Ove...
  • Regulatory NewsRegulatory News

    PDUFA VII: FDA and industry set priorities in first round of negotiations

    After kicking off the Prescription Drug User Fee Act (PDUFA) reauthorization process in July, the US Food and Drug Administration (FDA) has released the first set of meeting summaries in its ongoing negotiations with industry that will shape its prescription drug review program from FY2023-2027.   The meeting summaries, while brief, provide insights into what FDA and industry hope to get out of the multi-billion-dollar agreement, with representatives from government ...
  • Regulatory NewsRegulatory News

    Lack of product-specific guidance slows ANDAs: FDA study

    Researchers at the US Food and Drug Administration (FDA) found that, for drugs that are new chemical entities, generic submissions were more likely when the reference brand-name drug generated more revenue.   Looking into other factors that predict that an abbreviated new drug application (ANDA) will be filed for a reference drug, the investigators also found that sponsors were less likely to file ANDAs for complex drugs.   In a retrospective study examining 400 br...
  • ReconRecon

    Recon: Novartis buys Vedere Bio for $150M upfront; Gilead reports $873M in remdesivir sales

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US A P value of 0.38? NEJM results raise new questions for Eli Lilly's vaunted Covid antibody ( Endpoints ) ( NEJM ) Regeneron Covid-19 Therapy Reduces Viral Load, Need for Care ( Bloomberg ) ( Endpoints ) ( NBC ) Antibody drugs seem to work. But the virus is moving faster than we can make them ( STAT ) Moderna on track to report late-stage COVID-19 vaccine data ...
  • RoundupsRoundups

    FDA Approvals Roundup: Remdesivir, Eysuvis, Sklice

    A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA).   New approvals Remdesivir gets the go-ahead for COVID-19 Gilead Sciences’ Veklury (remdesivir) has been approved for the treatment of older children and adults who are hospitalized with COVID-19. [SEE: Remdesivir receives FDA approval for COVID-19 , Regulatory Focus , 22 October 2020]   New indications Eysuvis okayed for short-term treatment of dry e...
  • ReconRecon

    Recon: Sanofi, GSK to supply 200M vaccine doses to COVAX scheme; US strikes deal for Lilly’s COVID antibody drug

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US Pfizer CEO All but Rules Out Vaccine Before Election Day ( NYTimes ) ( FT ) US strikes deal with Lilly for potential COVID-19 antibody drug ( Reuters ) ( Endpoints ) ( Press ) Lawmakers release trove of Purdue documents detailing Sackler family’s involvement in opioid sales ( STAT ) I'm the FDA point person on COVID-19 vaccines. We'll make sure they're safe an...
  • Regulatory NewsRegulatory News

    MDUFA V: Industry wants fine tuning while FDA seeks expansion

    The US Food and Drug Administration (FDA) kicked off the negotiation process that will inform the fifth iteration of the Medical Device User Fee Amendments (MDUFA V) program via a virtual public meeting on Tuesday.   The meeting, initially scheduled to take place in April, is the starting point for the negotiations with industry and discussions with stakeholders that will shape FDA’s medical device program from FY2023-FY2027.   During the meeting, FDA officials...
  • Regulatory NewsRegulatory News

    FDA clarifies reference-listed drugs, other ANDA terms in final guidance

    Generic drugmakers have received finalized guidance from the US Food and Drug Administration. In finalizing a 2017 draft, the agency gives sponsors of abbreviated new drug applications (ANDAs) information about how to identify reference listed drugs (RLDs), further details on reference standards, and what forms the basis for an ANDA submission.   “The guidance is intended to clarify what these terms mean and how to accurately use these terms in an ANDA,” said FDA in an...
  • ReconRecon

    Recon: Exact Sciences nabs rival Thrive for $2B+; Lilly's COVID antibody flops

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US Third wave of coronavirus infections in the U.S.? More like 'wildfire,' epidemiologist says ( NBC ) U.S. Coronavirus Cases Surpass Summer Peak And Are Climbing Higher Fast ( NPR ) Covid hospitalizations rising in 36 states as U.S. hits another record for average new cases ( CNBC ) Fauci on latest surge: 'No matter how you look at it, it's not good news' ( The ...
  • Regulatory NewsRegulatory News

    FDA delays enforcement of some DSCSA provisions by three years

    The US Food and Drug Administration (FDA) last week announced it will again delay enforcement of a provision of the Drug Supply Chain Security Act (DSCSA) that would require wholesalers to verify saleable returned drugs they intend to further distribute.   “FDA does not intend to take action against wholesale distributors who do not, prior to November 27, 2023, verify the product identifier prior to further distributing returned product as required under section 582(...
  • FDA-state compounding MOU now available for signing

    A standard memorandum of understanding between the US Food and Drug Administration (FDA) and the states regarding interstate distribution of compounded drugs is available for signing.   State boards of pharmacy or other state agencies have 365 days to sign the document. After that time, FDA intends to begin enforcing a provision of the Federal Food, Drug and Cosmetic Act (FD&C Act) that prohibits states that have not signed the MOU from distributing more than 5% of a c...